Ultra-high performance liquid chromatography-mass spectrometry for the metabolomic analysis of urine in colorectal cancer.
We report here the results of a pilot study in which ultra-high performance liquid chromatography/time-of- flight-mass spectrometry (UPLC/TOF-MS) and multivariate statistical analysis (supervised partial least squares discriminant analysis, PLS-DA) were applied for urinary metabolite profiling and data interpretation. The results of the PLS-DA indicated that the metabolic pattern as a whole was significantly different between the groups of preoperative colorectal cancer (CRC) patients, postoperative CRC patients, and healthy volunteers, respectively. The preoperative group of patients showed significantly increased levels of low-molecular weight compounds (LMC) MW 283 and MW 234 in comparison to the group of healthy volunteers group. After the operation, the levels of these two LMC significantly decreased. These preliminary results suggest that the UPLC-MS-based method coupled with pattern recognition will likely lead to procedures with the potential to be clinically applicable for the diagnosis of CRC and, consequently, to an improvement in patient prognosis.
Ma
Yan-Lei
YL
Department of Surgery, The Sixth People’s Hospital Affiliated to Shanghai Jiaotong University, 600 Yishan Road, Shanghai 200233, China.
Qin
Huan-Long
HL
Liu
Wei-Jie
WJ
Peng
Jia-Yuan
JY
Huang
Long
L
Zhao
Xiao-Ping
XP
Cheng
Yi-Yu
YY
D000368:Aged; D014408:Biomarkers, Tumor / Q000652:urine*; D016022:Case-Control Studies; D002681:China; D002851:Chromatography, High Pressure Liquid; D003082:Colectomy; D015179:Colorectal Neoplasms / Q000473:pathology / Q000601:surgery / Q000652:urine*; D016002:Discriminant Analysis; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D016018:Least-Squares Analysis; D008297:Male; D055432:Metabolomics / Q000379:methods*; D008875:Middle Aged; D008970:Molecular Weight; D010363:Pattern Recognition, Automated; D010865:Pilot Projects; D021241:Spectrometry, Mass, Electrospray Ionization; D016896:Treatment Outcome
D014408:Biomarkers, Tumor